The Likelihood of Reaching Substantial Clinical Benefit Following an Interlaminar Dynamic Spacer for Chronic Low Back Pain: A Clinical and Radiological Analysis of a Prospective Cohort.

Related Articles

The Likelihood of Reaching Substantial Clinical Benefit Following an Interlaminar Dynamic Spacer for Chronic Low Back Pain: A Clinical and Radiological Analysis of a Prospective Cohort.

World Neurosurg. 2017 Feb 24;:

Authors: Bae J, Lee SM, Lee SH, Shin SH, Kim HJ, Kim KH

Abstract
PURPOSE: Chronic low back pain (CLBP) often causes disabling pain that impairs a patient's quality of life. Surgical treatment is recommended for patients who do not respond to conservative treatments lasting more than six months. The purpose of this study is to present results after the use of an interlaminar dynamic spacer for CLBP.
MATERIALS AND METHODS: We enrolled consecutive patients with CLBP irresponsive to more than six months of conservative treatment into the present study. Included patients underwent an interlaminar dynamic spacer insertion without direct decompression. We assessed radiographic parameters and Health-related quality of life (HRQoL) data included VAS back/leg pain and Oswestry Disability Index (ODI) scores. Substantial clinical benefit (SCB) achievement was assessed.
RESULTS: Thirty-five patients (average 47.8 years; 21 female) were included. The mean preoperative symptom duration was 29.6 months. Surgeries involved 1-level (n=18) and 2-levels (n=17) procedures. Operative levels included L4-5 (n=8), L5-S1 (n=10), L3-4-5 (n-2), and L4-5-S1 (n=15). The average follow-up period was 16.6 months. After the procedure, all radiographic parameters (including disc height, segmental extension angle and foraminal area) improved significantly. All preoperative HRQoL parameters improved significantly at the final follow-up. SCB achievement was observed in 75.8% of the cases in ODI, and in 72.7% and 84.8% of the cases for VAS back and leg pain, respectively.
CONCLUSION: An interlaminar dynamic spacer significantly improves HRQoL scores in patients with CLBP who do not respond to conservative treatment. While encouraging, these results should be confirmed with studies assessing a larger cohort and a longer follow-up.

PMID: 28242487 [PubMed - as supplied by publisher]

http://ift.tt/2lbsxG9